デフォルト表紙
市場調査レポート
商品コード
1491640

バイオアベイラビリティ向上技術・サービス市場:製品、製剤、用途、エンドユーザー別-2024-2030年の世界予測

Bioavailability Enhancement Technologies & Services Market by Offering (Services, Technologies), Drug Formulation (Inhalable Formulations, Injectable Formulations, Oral Formulations), Application, End-User - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
バイオアベイラビリティ向上技術・サービス市場:製品、製剤、用途、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

バイオアベイラビリティ向上技術・サービス市場規模は2023年に20億米ドルと推定され、2024年には21億5,000万米ドルに達し、CAGR 7.67%で2030年には33億7,000万米ドルに達すると予測されています。

バイオアベイラビリティ向上技術・サービスは、医薬品有効成分の血流への吸収速度や吸収範囲を改善するために設計された様々な方法や支援システムを指します。これらの技術は、特に溶解性や浸透性の低い医薬品の有効性を高めるために極めて重要です。市場の成長は、ナノ粒子やリポソーム送達システムなどの技術的進歩、より効果的な治療法を求める慢性疾患の増加、FDAやEMAなどの機関による規制支援によって大きく左右されます。しかし、開発コストの高さ、規制の複雑さ、潜在的利用者の限られた認識、特定の薬剤分子に関連する技術的困難といった課題は依然として残っています。とはいえ、ナノテクノロジー、個別化医療、バイオ医薬品の進歩は、成長と革新の新たな道を切り開くものと期待されています。

主な市場の統計
基準年[2023] 20億米ドル
予測年[2024] 21億5,000万米ドル
予測年[2030] 33億7,000万米ドル
CAGR(%) 7.67%

地域別の洞察

バイオアベイラビリティ向上技術の世界市場は、ヘルスケアインフラの進歩、旺盛な研究開発投資、効果的な医薬品に対する需要の高まりによって大きな成長を遂げています。北米と南米をカバーする南北アメリカは、高い医療費と最先端の医薬品に対する消費者の需要によって牽引されており、米国とカナダは研究開発と特許でリードしています。米国では、洗練された医療制度がこの市場を後押ししており、新規デリバリーシステムやナノ粒子技術による革新的な医薬品開拓が重視されています。EMEA(欧州・中東・アフリカ)地域は、欧州では厳しい規制により高品質の医薬品が優先され、中東ではヘルスケア・インフラが整備される中で先進的な治療に投資し、アフリカでは手頃な価格と現地生産能力に重点を置くなど、多様な顧客ニーズを示しています。これらの地域では、持続可能で患者にやさしいバイオアベイラビリティ・テクノロジーの研究と投資が継続的に進められています。地域別では、中国、日本、インドの消費者の間で健康意識が高まっていることから、アジア太平洋地域が多様で急成長している市場として際立っています。投資動向からは、革新的な送達システムとコスト効率の高いソリューションに注目が集まっていることがうかがえます。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、バイオアベイラビリティ向上技術・サービス市場におけるベンダーの市場ポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。

市場シェア分析

市場シェア分析は、バイオアベイラビリティ向上技術・サービス市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査対象期間の累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。

戦略分析と推奨

戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、バイオアベイラビリティ向上技術・サービス市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 慢性疾患の蔓延
      • 患者のコンプライアンスと効果的な治療法の需要
      • 政府の支援政策と規制
    • 抑制要因
      • 高度なバイオアベイラビリティ技術の開発コストが高い
    • 機会
      • ドラッグデリバリー技術の進歩
      • バイオアベイラビリティ向上剤と新薬化合物の組み合わせにおける革新
    • 課題
      • 特定の薬物分子に関連する特定の生物学的利用能に関連する問題
  • 市場セグメンテーション分析
    • 提供内容:バイオアベイラビリティ向上戦略の開発と最適化に関するアドバイスを製薬会社に提供するコンサルティングサービスの採用拡大
    • 用途:低用量で患者の血圧、コレステロール値、心拍数を管理する心血管疾患への適合性
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 バイオアベイラビリティ向上技術・サービス市場:提供別

  • サービス
  • テクノロジー

第7章 バイオアベイラビリティ向上技術・サービス市場薬剤処方別

  • 吸入製剤
  • 注射剤
  • 経口製剤
  • 局所用製剤

第8章 バイオアベイラビリティ向上技術・サービス市場:用途別

  • 心血管疾患
  • 中枢神経系疾患
  • 消化器疾患
  • 感染症
  • 腫瘍学

第9章 バイオアベイラビリティ向上技術・サービス市場:エンドユーザー別

  • 学術調査機関
  • バイオテクノロジー企業
  • 契約調査機関(CRO)
  • 製薬会社

第10章 南北アメリカのバイオアベイラビリティ向上技術・サービス市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域のバイオアベイラビリティ向上技術・サービス市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカのバイオアベイラビリティ向上技術・サービス市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • ロンザ、AIを活用したルート探索サービスで革新を起こし、低分子 API開発を強化
    • ロンザ、タンパク質ベースの治療薬の肺への送達を強化するためにスプレー乾燥サービスを拡大
    • カタレントとグルネンタールが疼痛管理分子の臨床開発を加速するために協力
  • 戦略分析と提言

第14章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET RESEARCH PROCESS
  • FIGURE 2. BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET DYNAMICS
  • FIGURE 7. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY CONSULTANCY SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY CONSULTANCY SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY CRYOGENIC TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY CRYOGENIC TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY HOT-MELT EXTRUSION (HME), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY HOT-MELT EXTRUSION (HME), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY LIPID-BASED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY LIPID-BASED DRUG DELIVERY SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SOLID DISPERSION TECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SOLID DISPERSION TECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY INHALABLE FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY INHALABLE FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY INJECTABLE FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY INJECTABLE FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 101. CANADA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 102. CANADA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 113. MEXICO BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 114. MEXICO BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 125. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 126. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 152. AUSTRALIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 154. AUSTRALIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. CHINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 164. CHINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 165. CHINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 166. CHINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. INDIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 176. INDIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 177. INDIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 178. INDIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. INDONESIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 188. INDONESIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 189. INDONESIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 190. INDONESIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 199. JAPAN BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 200. JAPAN BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 201. JAPAN BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 202. JAPAN BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 211. MALAYSIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 212. MALAYSIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 213. MALAYSIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 214. MALAYSIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 224. PHILIPPINES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 226. PHILIPPINES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 235. SINGAPORE BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 236. SINGAPORE BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 237. SINGAPORE BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 238. SINGAPORE BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH KOREA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH KOREA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY DRUG FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES & SERVICES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 259. TAIWA
目次
Product Code: MRR-3A68B83976AE

[194 Pages Report] The Bioavailability Enhancement Technologies & Services Market size was estimated at USD 2.00 billion in 2023 and expected to reach USD 2.15 billion in 2024, at a CAGR 7.67% to reach USD 3.37 billion by 2030.

Bioavailability Enhancement Technologies & Services refer to a range of methods and support systems designed to improve the rate and extent to which active pharmaceutical ingredients are absorbed into the bloodstream. These technologies are crucial for increasing the effectiveness of medications, especially those with poor solubility or permeability. Market growth is largely influenced by technological advancements, including nanoparticle and liposomal delivery systems, the increasing prevalence of chronic diseases demanding more effective treatments, and regulatory support from agencies such as the FDA and EMA. However, challenges such as the high costs of development, regulatory complexities, limited awareness among potential users, and technical difficulties related to specific drug molecules still persist. Nevertheless, advancements in nanotechnology, personalized medicine, and biopharmaceuticals are expected to create new avenues for growth and innovation.

KEY MARKET STATISTICS
Base Year [2023] USD 2.00 billion
Estimated Year [2024] USD 2.15 billion
Forecast Year [2030] USD 3.37 billion
CAGR (%) 7.67%

Regional Insights

The global market for bioavailability enhancement technologies is experiencing significant growth driven by advancements in healthcare infrastructure, robust R&D investments, and the increasing demand for effective pharmaceutical products. The Americas, covering North and South America, are driven by high healthcare expenditures and consumer demand for cutting-edge pharmaceuticals, with the US and Canada leading in R&D and patents. In the United States, this market is bolstered by a sophisticated healthcare system, emphasizing innovative drug development through novel delivery systems and nanoparticle technology. The EMEA region exhibits varied customer needs, with Europe prioritizing high-quality pharmaceuticals due to stringent regulations, the Middle East investing in advanced treatments amid growing healthcare infrastructure, and Africa focusing on affordability and local production capabilities. Across these regions, research and investments are continually advancing sustainable and patient-friendly bioavailability technologies. Regionally, the Asia Pacific stands out as a diverse and rapidly growing market due to increasing health consciousness among consumers in China, Japan, and India. Investment trends suggest a focus on innovative delivery systems and cost-effective solutions.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Bioavailability Enhancement Technologies & Services Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising prevalence of chronic diseases
      • Patient compliance and demand for effective therapies
      • Supportive government policies and regulations
    • Market Restraints
      • High cost of development in advanced bioavailability technologies
    • Market Opportunities
      • Advancement in drug delivery technologies
      • Innovations in combining bioavailability enhancers with new drug compounds
    • Market Challenges
      • Issues associated with specific bioavailability related to certain drug molecules
  • Market Segmentation Analysis
    • Offering: Increasing adoption of consultancy services for guidance to pharmaceutical companies in developing and optimizing bioavailability enhancement strategies
    • Application: Suitability in cardiovascular diseases to manage blood pressure, cholesterol levels, and heart rate of patients with lower doses
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Bioavailability Enhancement Technologies & Services Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Bioavailability Enhancement Technologies & Services Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Lonza Innovates with AI-Enabled Route Scouting Service to Enhance Small Molecule API Development

Lonza introduced its AI-enabled Route Scouting Service (RSS) aimed at streamlining the identification of synthetic routes for novel Active Pharmaceutical Ingredients (APIs). Leveraging Lonza's extensive chemical supply chain intelligence and in-house expertise, this service incorporates advanced AI technology from Elsevier's Reaxys to address the increasing complexity of small molecule APIs. The RSS integrates Lonza's process research and development (R&D) proficiency with comprehensive supply chain databases and AI-enabled computer-aided synthesis planning technology (CSPT). This combination aims to provide synthetic pathways that enhance supply chain resilience and offer optimal route designs for both clinical and commercial manufacturing. [Published On: 2024-04-30]

Lonza Expands Spray-Drying Services to Enhance Pulmonary Delivery of Protein-Based Therapies

Lonza expanded its service offerings for spray-drying proteins aimed at pulmonary delivery. This new service, available at Lonza's Bend facility in the US, supports both clinical and commercial manufacturing at a kilogram scale. The Bend site serves as Lonza's Center of Excellence for respiratory delivery. Protein-based therapies for respiratory diseases have usually been administered via intravenous or subcutaneous injections, which are costly and require patient compliance. Lonza aims to advance the development of inhaled biologics from early-phase production to commercial supply. [Published On: 2024-03-27]

Catalent and Grunenthal Collaborate to Expedite Clinical Development of Pain Management Molecule

Catalent collaborated with Grunenthal to design and manufacture a bioavailability-enhanced oral formulation of a small molecule from Grunenthal's pipeline. Positive preclinical results have advanced this molecule to first-in-human studies, with Catalent leveraging its OptiForm Solution Suite platform for rapid characterization and optimization of the formulation. [Published On: 2023-03-15]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Bioavailability Enhancement Technologies & Services Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Bioavailability Enhancement Technologies & Services Market, highlighting leading vendors and their innovative profiles. These include Adare Pharma Solutions, Alexion Pharmaceuticals, Ardena, Catalent, Inc., Corden Pharma International GmbH, Eurofins Scientific SE, Ferring Pharmaceuticals, Formulex Ltd., Hovione, Janssen Pharmaceuticals, Lonza Group AG, Mayne Pharma Group Limited, Merck KGaA, Novo Nordisk, Pace Analytical Services, LLC, Particle Sciences, Pensatech Pharma GmbH, Quotient Sciences, Renejix Pharma Solutions, The Lubrizol Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Bioavailability Enhancement Technologies & Services Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Offering
    • Services
      • Analytical Testing
      • Consultancy Services
    • Technologies
      • Cryogenic Technologies
      • Hot-Melt Extrusion (HME)
      • Lipid-Based Drug Delivery Systems
      • Solid Dispersion Technology
  • Drug Formulation
    • Inhalable Formulations
    • Injectable Formulations
    • Oral Formulations
    • Topical Formulations
  • Application
    • Cardiovascular Diseases
    • Central Nervous System Disorders
    • Gastrointestinal Diseases
    • Infectious Diseases
    • Oncology
  • End-User
    • Academic & Research Institutes
    • Biotechnology Firms
    • Contract Research Organizations (CROs)
    • Pharmaceutical Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases
      • 5.1.1.2. Patient compliance and demand for effective therapies
      • 5.1.1.3. Supportive government policies and regulations
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development in advanced bioavailability technologies
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in drug delivery technologies
      • 5.1.3.2. Innovations in combining bioavailability enhancers with new drug compounds
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with specific bioavailability related to certain drug molecules
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Increasing adoption of consultancy services for guidance to pharmaceutical companies in developing and optimizing bioavailability enhancement strategies
    • 5.2.2. Application: Suitability in cardiovascular diseases to manage blood pressure, cholesterol levels, and heart rate of patients with lower doses
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Bioavailability Enhancement Technologies & Services Market, by Offering

  • 6.1. Introduction
  • 6.2. Services
  • 6.3. Technologies

7. Bioavailability Enhancement Technologies & Services Market, by Drug Formulation

  • 7.1. Introduction
  • 7.2. Inhalable Formulations
  • 7.3. Injectable Formulations
  • 7.4. Oral Formulations
  • 7.5. Topical Formulations

8. Bioavailability Enhancement Technologies & Services Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases
  • 8.3. Central Nervous System Disorders
  • 8.4. Gastrointestinal Diseases
  • 8.5. Infectious Diseases
  • 8.6. Oncology

9. Bioavailability Enhancement Technologies & Services Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Biotechnology Firms
  • 9.4. Contract Research Organizations (CROs)
  • 9.5. Pharmaceutical Companies

10. Americas Bioavailability Enhancement Technologies & Services Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Bioavailability Enhancement Technologies & Services Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Bioavailability Enhancement Technologies & Services Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Lonza Innovates with AI-Enabled Route Scouting Service to Enhance Small Molecule API Development
    • 13.3.2. Lonza Expands Spray-Drying Services to Enhance Pulmonary Delivery of Protein-Based Therapies
    • 13.3.3. Catalent and Grunenthal Collaborate to Expedite Clinical Development of Pain Management Molecule
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio